EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial

Deborah Konopnicki iD, Christine Gilles, Yannick Manigart, Patricia Barlow, Anca Reschner, Coca Necsoi, Marc Delforge, Davy Vanden Broeck iD, Nicolas Dauby iD, Stéphane De Wit

Clinical Infectious Diseases · 30.04.2026 · 82 (4) · 673-681

DOI: 10.1093/cid/ciaf241 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.05.2025. Verfasst von Deborah Konopnicki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: HIV Infections, Papillomavirus Infections, Immunogenicity, Vaccine, Papillomavirus Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: King Baudouin Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The World Health Organization recommends 2 doses of human papillomavirus (HPV) vaccine for adults without human immunodeficiency virus (HIV) but 3 doses in persons with HIV. There are no immunogenicity data on the 2-dose schedule in women with HIV (WWH).

Methods

This was a prospective study comparing 2 doses (months 0 and 6) versus 3 (months 0, 2, and 6) doses of 9-valent vaccine (Gardasil 9, Merck Sharp & Dohme) in WWH (15–40 years), on antiretrovirals with HIV RNA <400 copies/mL, enrolled during 2018–2021. After an open-label phase assessing safety (n = 45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was noninferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to the COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n = 22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n = 100) and per protocol on the whole cohort (n = 167).

Results

Participants’ median age was 35 years, median CD4 count was 649 cells/µL, and 16 missed the month 7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined noninferiority criteria. At month 7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2–2.4 log10). There were no serious adverse events; participants with 3 doses experienced local reactions more frequently (82% vs 60% for 2 doses, P = .027) with more symptoms and longer duration.

Conclusions

In women with well-controlled HIV, 2 doses of 9-valent HPV vaccine is noninferior to 3 doses in terms of seroconversion and is associated with less reactogenicity. Clinical Trials Registration NCT03391921; EUDRACT 2018-000228-33; CTIS-EMA 2024-520419-42-00.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPapillomavirus InfectionsImmunogenicity, VaccinePapillomavirus VaccinesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18HumansFemaleAdultProspective StudiesYoung AdultImmunization ScheduleAdolescentAntibodies, ViralCOVID-19SeroconversionHuman Papillomavirus Viruses

Stichwörter der Autor:innen

9-valent vaccineHIVHPVimmunogenicitywomen

Substanzen

Papillomavirus VaccinesAntibodies, ViralHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Autor:innen und Institutionen

  • Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Gynecology Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Laboratory of Molecular Pathology Algemeen Medisch Laboratorium, Sonic Healthcare Belgium and Belgian National Reference Laboratory for Human Papillomavirus, Antwerp, Belgium.

ORCID-Profile: Deborah Konopnicki, Davy Vanden Broeck, Nicolas Dauby

Förderung

  • King Baudouin Foundation

Zitieren

APA

Konopnicki, D., Gilles, C., Manigart, Y., Barlow, P., Reschner, A., Necsoi, C., Delforge, M., Vanden Broeck, D., Dauby, N., & De Wit, S. (2026). Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial. Clinical Infectious Diseases, 82(4), 673-681. https://doi.org/10.1093/cid/ciaf241

Vancouver

Konopnicki D, Gilles C, Manigart Y, Barlow P, Reschner A, Necsoi C, et al. Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial. Clinical Infectious Diseases. 2026;82(4):673-681. doi:10.1093/cid/ciaf241

BibTeX
@article{Konopnicki2026,
  author = {Konopnicki, Deborah and Gilles, Christine and Manigart, Yannick and Barlow, Patricia and Reschner, Anca and Necsoi, Coca and Delforge, Marc and Vanden Broeck, Davy and Dauby, Nicolas and De Wit, Stéphane},
  title = {Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {4},
  pages = {673--681},
  doi = {10.1093/cid/ciaf241}
}
Kostenlos starten →